Cogent Biosciences Inc Dossier - Source-backed chat

Cogent Biosciences Inc

COGTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.55

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $31.59Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $5.5B

Enterprise Value $5.3B

Shares Outstanding 181.1M diluted

Next Earnings Date30 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cogent Biosciences is transitioning from a clinical-stage biotechnology company to a commercial-stage entity, driven by its lead asset bezuclastinib. Bezuclastinib is a highly selective and potent KIT inhibitor targeting KIT D816V and exon 17 mutations, which are key drivers in systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). With positive registrational data from the PEAK (GIST), SUMMIT (NonAdvSM), and APEX (AdvSM) trials, Cogent has established a robust clinical profile that positions bezuclastinib as a potential best-in-class therapy. Backed by a strong cash position of over $860 million, which provides a runway into 2028, Cogent is well-capitalized to execute its upcoming commercial launches in late 2026, pending FDA approvals.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$35.00

Mean target$54.25

High · most bullish analyst$72.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$35.00

The FDA issues a Complete Response Letter (CRL) or requests additional clinical data for bezuclastinib, delaying commercialization timelines. Alternatively, the commercial launch faces slow adoption due to aggressive pricing or strong market entrenchment by competitors. High commercialization and ongoing clinical trial expenses accelerate cash burn, forcing dilutive equity raises before 2028.

Base CaseCentral scenario

$54.25

Matches the consensus mean

Bezuclastinib receives FDA approvals for second-line GIST and NonAdvSM by late 2026. The commercial rollout proceeds as planned in the first half of 2027, establishing bezuclastinib as a standard-of-care option. R&D expenses remain controlled, and the cash runway safely extends into 2028, allowing the company to reach commercial viability without dilutive financing.

Bull CaseUpside scenario

$72.00

The FDA approves bezuclastinib for both second-line GIST and NonAdvSM ahead of or on their respective PDUFA dates in late 2026. Commercial launch in the US is highly successful, capturing significant market share from incumbents like avapritinib due to a superior safety and tolerability profile. Early-stage pipeline assets, particularly the JAK2 V617F mutant-selective inhibitor, demonstrate strong clinical proof-of-concept, driving upward valuation revisions.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated clinical profile of lead asset bezuclastinib, showing high selectivity for KIT D816V and exon 17 mutations with a favorable safety and tolerability profile.
Multiple near-term regulatory catalysts, including FDA PDUFA dates for second-line GIST (November 30, 2026) and NonAdvSM (December 30, 2026).
Robust balance sheet with approximately $866 million in cash and marketable securities, providing a runway into 2028 and mitigating near-term financing risks.

Key Investment Risks

Regulatory risks inherent in FDA approval processes, where unexpected delays or requests for additional data could impact commercial timelines.
Commercial execution risks, as Cogent prepares for its first product launch and must compete against established therapies in the rare disease and oncology markets.
High operational cash burn driven by late-stage clinical trials and commercial preparation expenses.

Thesis Invalidation Triggers

FDA rejection or significant delay of the New Drug Applications (NDAs) for bezuclastinib.
Safety signals emerging from ongoing clinical trials or expanded access programs that compromise the drug's tolerability profile.
A rapid acceleration in cash burn that shortens the projected runway significantly below the 2028 target.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.